Yun Dai Selected Research

BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)

5/2011	HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
8/2008	Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.
7/2007	Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
4/2005	Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
8/2004	A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
7/2004	Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yun Dai Research Topics

Disease

62	Neoplasms (Cancer) 12/2023 - 06/2003
29	Leukemia 01/2020 - 03/2002
26	Multiple Myeloma 10/2023 - 11/2002
12	Mitochondrial Diseases (Mitochondrial Disease) 07/2007 - 06/2003
9	Carcinogenesis 01/2022 - 05/2006
8	Carcinoma (Carcinomatosis) 01/2022 - 05/2002
8	Colitis 01/2022 - 04/2013
8	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 07/2008
8	Colonic Neoplasms (Colon Cancer) 05/2014 - 06/2008
7	Inflammation (Inflammations) 01/2022 - 03/2009
6	Infections 01/2023 - 09/2009
6	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020 - 04/2004
6	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 05/2011 - 07/2004
5	Ovarian Neoplasms (Ovarian Cancer) 01/2023 - 01/2016
5	Breast Neoplasms (Breast Cancer) 01/2023 - 11/2005
5	Hematologic Neoplasms (Hematological Malignancy) 08/2019 - 07/2004
5	Hypoxia (Hypoxemia) 01/2019 - 08/2005
5	Obesity 06/2015 - 05/2006
4	Neoplasm Metastasis (Metastasis) 03/2022 - 04/2012
4	Stomach Neoplasms (Stomach Cancer) 01/2022 - 05/2006
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2016 - 06/2008
4	Myeloid Leukemia (Leukemia, Myelocytic) 12/2003 - 03/2002
3	Prostatic Neoplasms (Prostate Cancer) 12/2023 - 12/2017
3	Hepatocellular Carcinoma (Hepatoma) 01/2023 - 03/2014
3	Glioma (Gliomas) 08/2022 - 04/2012
3	Lymphatic Metastasis 01/2022 - 01/2019
3	Insulin Resistance 01/2019 - 03/2010
3	Colitis-Associated Neoplasms 01/2018 - 05/2014
3	Body Weight (Weight, Body) 06/2015 - 05/2006
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 05/2011 - 01/2004
2	Pain (Aches) 01/2024 - 01/2022
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2022 - 01/2021

Drug/Important Bio-Agent (IBA)

22	Histone Deacetylase InhibitorsIBA 10/2021 - 07/2002
14	7-hydroxystaurosporine (UCN 01)IBA 05/2013 - 05/2002
12	Proteins (Proteins, Gene)FDA Link 11/2019 - 03/2002
12	Bortezomib (Velcade)FDA Link 01/2019 - 10/2003
10	Histone Deacetylases (Histone Deacetylase)IBA 10/2019 - 12/2003
10	alvocidib (flavopiridol)IBA 01/2018 - 03/2002
10	Vorinostat FDA Link 06/2013 - 12/2003
9	Proteasome InhibitorsIBA 01/2019 - 10/2003
9	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 12/2008
9	CaspasesIBA 05/2014 - 03/2002
9	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2007 - 04/2003
8	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 10/2004
8	Imatinib Mesylate (Gleevec)FDA Link 01/2019 - 11/2002
8	LigandsIBA 09/2015 - 12/2003
8	Butyric Acid (Butanoic Acid)IBA 04/2005 - 07/2002
7	2- (2- chloro- 4- iodophenylamino)- N- cyclopropylmethoxy- 3,4- difluorobenzamideIBA 04/2012 - 11/2002
7	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 04/2012 - 11/2002
7	Cytochromes c (Cytochrome c)IBA 07/2007 - 05/2002
6	Biomarkers (Surrogate Marker)IBA 10/2023 - 05/2013
6	Peptides (Polypeptides)IBA 01/2022 - 04/2004
6	Small Interfering RNA (siRNA)IBA 01/2018 - 08/2004
6	embelinIBA 01/2018 - 06/2009
6	Phosphotransferases (Kinase)IBA 06/2013 - 11/2002
5	MicroRNAs (MicroRNA)IBA 01/2023 - 01/2013
5	EnzymesIBA 01/2022 - 05/2014
5	Messenger RNA (mRNA)IBA 01/2021 - 08/2005
5	Apoptosis Regulatory ProteinsIBA 01/2020 - 02/2006
5	Interleukin-6 (Interleukin 6)IBA 01/2020 - 12/2004
5	PPAR gammaIBA 06/2009 - 06/2008
5	NF-kappa B (NF-kB)IBA 03/2009 - 09/2003
4	Immune Checkpoint InhibitorsIBA 12/2023 - 01/2022
4	LipidsIBA 12/2023 - 12/2008
4	SolutionsIBA 01/2022 - 01/2010
4	CytokinesIBA 01/2020 - 12/2003
4	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 08/2012 - 04/2004
4	Checkpoint Kinase 1IBA 08/2012 - 12/2006
4	X-Linked Inhibitor of Apoptosis ProteinIBA 09/2009 - 06/2008
4	Caspase 3 (Caspase-3)IBA 09/2009 - 03/2005
4	Caspase 8 (Caspase-8)IBA 02/2005 - 05/2002
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 07/2008
3	PanobinostatIBA 10/2021 - 04/2012
3	oxidized low density lipoproteinIBA 01/2019 - 10/2015
3	Dextran SulfateIBA 01/2018 - 04/2013
3	Drug CombinationsIBA 01/2017 - 11/2005
3	LeptinIBA 06/2015 - 08/2009
3	ABT-737IBA 01/2014 - 01/2007
3	Reactive Oxygen Species (Oxygen Radicals)IBA 12/2012 - 06/2004
3	AZD 6244IBA 04/2012 - 03/2008
3	entinostat (MS 275)IBA 05/2011 - 04/2004
3	Troglitazone (Rezulin)FDA Link 09/2008 - 06/2008
3	RoscovitineIBA 01/2007 - 04/2003
3	U 0126 (UO 126)IBA 12/2003 - 11/2002
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2003 - 07/2002
2	Prostate-Specific Antigen (Semenogelase)IBA 12/2023 - 12/2017
2	AntigensIBA 12/2023 - 04/2004
2	RNA (Ribonucleic Acid)IBA 01/2023 - 01/2019
2	Lactic Acid (Lactate)FDA LinkGeneric 01/2023 - 05/2014
2	NeurotensinIBA 08/2022 - 02/2015
2	B7-H1 AntigenIBA 03/2022 - 09/2015
2	ElafinIBA 01/2022 - 01/2019
2	Dextrans (Dextran)FDA Link 01/2022 - 01/2020
2	Ion Channels (Ion Channel)IBA 01/2022 - 12/2020
2	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2022 - 01/2020
2	Inhibitor of Apoptosis ProteinsIBA 10/2021 - 01/2019
2	HydrogelsIBA 09/2021 - 03/2014

Therapy/Procedure

22	Therapeutics 01/2023 - 08/2003
7	Drug Therapy (Chemotherapy) 01/2020 - 06/2008
3	Immunotherapy 12/2023 - 01/2020